---
id: antimicrobials_imipenem-relebactam-comparison_033
category: antimicrobials
tags: [antimicrobials, imipenem-relebactam, I-R, CRE, advanced-antibiotics, comparison]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Imipenem-Relebactam & Advanced Beta-Lactam Comparison

**Q:** What is imipenem-relebactam's profile, and how do you choose between CAZ-AVI, C-T, M-V, and I-R for CRE and MDR Gram-negatives?

**A:**

**Imipenem-Relebactam (I-R) Profile:**
- **Mechanism:** Imipenem + relebactam (diazabicyclooctane class A/C β-lactamase inhibitor)
- **Activity:** Restores imipenem activity against imipenem-resistant Enterobacterales and P. aeruginosa
- **Does NOT inhibit:** Class B (MBLs) or Class D (OXAs)
- **Performance vs non-MBL CRE:** 70.1% susceptible (lower than CAZ-AVI 94.9% or M-V 80.3%)
- **Evidence:** Insufficient clinical data per ESCMID (no formal CRE recommendations yet)

**Comparison Table: When to Use Which Agent**

| **Agent** | **BEST For** | **NOT For** | **Resistance Pattern** |
|-----------|--------------|-------------|------------------------|
| **CAZ-AVI** | KPC CRE, OXA-48, MDR Pseudomonas | MBL (NDM, VIM, IMP) | Use CAZ-AVI + aztreonam for MBL |
| **C-T** | **MDR/XDR Pseudomonas** (drug of choice) | CRE, Acinetobacter, anaerobes | Best anti-Pseudomonal |
| **M-V** | **KPC CRE** (highest potency) | MBL, OXA, Pseudomonas worse than others | First-line for KPC |
| **I-R** | Imipenem-resistant Enterobacterales, P. aeruginosa | MBL, OXA, lower CRE activity | Limited clinical data |

**Clinical Decision Algorithm:**

**If CRE suspected:**
1. **KPC-producing?** → M-V or CAZ-AVI (both excellent)
2. **OXA-48?** → CAZ-AVI preferred
3. **MBL (NDM, VIM)?** → CAZ-AVI + aztreonam
4. **Unknown?** → CAZ-AVI (broadest CRE coverage)

**If MDR Pseudomonas suspected:**
1. **First choice:** C-T (best anti-Pseudomonal)
2. **Alternative:** CAZ-AVI

**If both CRE + Pseudomonas possible:**
1. **CAZ-AVI** (covers both reasonably)

**Mnemonic: "CAZ Covers, C-T Crushes Pseudomonas, M-V Murders KPC"**
- **CAZ-AVI** = Covers broadest (CRE + Pseudomonas)
- **C-T** = Crushes Pseudomonas (best)
- **M-V** = Murders KPC (highest potency)

**Clinical Pearl:**
- Always get carbapenemase PCR or phenotypic testing to guide definitive therapy
- Local resistance patterns matter (antibiograms)
- Consider combination therapy for high-risk infections

**Media:** None

**Sources:** [PMC 2023 - Comparative activities against CRE], [Frontiers 2024 - Real-world I-R use], [UNMC CRE Drug Review], [Expert Review 2024 - Novel CRE treatments], [CID 2019 - CRE treatment options]
